$39,427.81 speaking Payment -- Gilead Sciences to Dr. Andrew Young

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Gilead Sciences made a $39.4K speaking payment to Andrew Young, a Hepatology specialist in City, SC. The total payment of $39,427.81 to Dr. Andrew Young from Gilead Sciences is for speaking engagements. This payment represents compensation for Dr. Young's role as faculty or speaker. The payment was made on October 30, 2025, indicating a recent engagement.

Patient Guidance: What This Payment Means for You

This payment is for a physician's professional services as a speaker, not for personal medical advice. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Payments for speaking engagements can vary widely based on the physician's expertise, the topic, and the duration of the engagement.

Regulatory Context: Sunshine Act Requirements

Payments to physicians for speaking services are reportable under the Sunshine Act, requiring disclosure of the nature of the payment and the amount.

Related Topics

This payment is related to the following healthcare transparency topics:

• speaking-fees
• speaker-honorarium
• pharmaceutical-payments
• gilead-sciences
• hepatology
• physician-compensation

Understanding speaking Payments

Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.

Frequently Asked Questions About This Payment

What was this $39.4K payment for?

This was a speaking payment of $39.4K from Gilead Sciences to Andrew Young, categorized as "Compensation for serving as faculty or as a speaker". The payment was reported under the Sunshine Act (CMS Open Payments).

Does Andrew Young accept pharmaceutical money?

Yes, Andrew Young received this $39.4K payment from Gilead Sciences. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Andrew Young's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this speaking payment?

A speaking payment of $39.4K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Hepatology?

To compare this payment against Hepatology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Hepatology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Andrew Young's relationship with Gilead Sciences?

The payment amount is substantial, suggesting a significant speaking role or multiple engagements. This $39.4K speaking payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Hepatology?

The payment type is specifically for 'speaking', differentiating it from other potential interactions.

What should patients do after learning about this payment?

This payment is for a physician's professional services as a speaker, not for personal medical advice.

What else should I know about this speaking payment?

The date of payment is in the future (2025), which might indicate a contract for future services.

Related Reports

• View Dr. Andrew Young's full payment report
• Gilead Sciences full spending report
• Browse all Hepatology payments
• Browse all payments in South Carolina
• Search for other payments